MedTrace Logo

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

NCT02345343 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-06-28

No results posted yet for this study

Summary

The primary objective of the study is to report adverse events of on-treatment AEs by the treating physicians during a specified 24-month study period in patients with venous thromboembolism at the sentinel site(s) for the National Center of Pharmacovigilance (CNFV) in Mexico.

Conditions

Interventions

DRUG

Apixaban

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-04
Primary Completion
2015-10-07
Completion
2015-10-07

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02345343 on ClinicalTrials.gov